Johnson & Johnson (TSX:JNJ)
32.50
+0.30 (0.93%)
Oct 6, 2026, 3:59 PM EST
Johnson & Johnson Employees
Johnson & Johnson had 138,200 employees as of December 28, 2025. The number of employees increased by 100 or 0.07% compared to the previous year.
Employees
138,200
Change (1Y)
100
Growth (1Y)
0.07%
Revenue / Employee
1.01M CAD
Profits / Employee
215.98K CAD
Market Cap
868.19B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 28, 2025 | 138,200 | 100 | 0.07% |
| Dec 29, 2024 | 138,100 | 6,200 | 4.70% |
| Dec 31, 2023 | 131,900 | -20,800 | -13.62% |
| Jan 1, 2023 | 152,700 | 11,000 | 7.76% |
| Jan 2, 2022 | 141,700 | 7,200 | 5.35% |
| Jan 3, 2021 | 134,500 | 2,300 | 1.74% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 4,900 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Cronos Group | 610 |
Johnson & Johnson News
- 13 hours ago - Johnson & Johnson price target raised to $290 from $287 at RBC Capital - TheFly
- 1 day ago - Johnson & Johnson price target raised to $303 from $298 at Citi - TheFly
- 4 days ago - Johnson & Johnson announces two-year data from Phase 3 ICONIC-TOTAL study - TheFly
- 4 days ago - Johnson & Johnson announces new ICOTYDE® (icotrokinra) data in difficult-to-treat plaque psoriasis with proven durability through 2-years, affirming its use as a powerful first line systemic therapy - PRNewsWire
- 5 days ago - New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause - Business Wire
- 7 days ago - Johnson & Johnson’s Imaavy shows efficacy in gMG Phase 2/3 trial - TheFly
- 7 days ago - Johnson & Johnson presents new data reinforcing sustained disease control and improved daily function achieved with IMAAVY® (nipocalimab-aahu) in generalized myasthenia gravis (gMG) - PRNewsWire
- 7 days ago - Johnson & Johnson price target raised to $285 from $270 at JPMorgan - TheFly